CalciMedica, Inc. Files 2023 Annual Report on Form 10-K

Ticker: CALC · Form: 10-K · Filed: Mar 28, 2024 · CIK: 1534133

Calcimedica, INC. 10-K Filing Summary
FieldDetail
CompanyCalcimedica, INC. (CALC)
Form Type10-K
Filed DateMar 28, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 10-K, CalciMedica, Financial Report, Biopharmaceutical, Corporate Update

TL;DR

<b>CalciMedica, Inc. (CALC) has filed its 2023 10-K report, detailing its financial performance and corporate changes, including a name change from Graybug Vision, Inc.</b>

AI Summary

CalciMedica, Inc. (CALC) filed a Annual Report (10-K) with the SEC on March 28, 2024. CalciMedica, Inc. filed its 2023 Annual Report on Form 10-K on March 28, 2024. The company was formerly known as Graybug Vision, Inc. and changed its name to CalciMedica, Inc. on March 22, 2023. The filing covers the fiscal year ending December 31, 2023. The company's principal business address is located in La Jolla, CA. CalciMedica, Inc. is in the Pharmaceutical Preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking CalciMedica, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of CalciMedica's financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's current standing and future prospects. The report includes details on various financial instruments and equity plans, such as convertible preferred stock, warrants, and employee stock options, offering insights into the company's capital structure and potential dilution.

Risk Assessment

Risk Level: medium — CalciMedica, Inc. shows moderate risk based on this filing. The company's financial disclosures are limited in this excerpt, making it difficult to assess its overall financial health, profitability, or cash burn rate, which are critical for a clinical-stage biopharmaceutical company.

Analyst Insight

Investors should review the full 10-K filing to understand CalciMedica's financial position, operational progress, and any forward-looking statements regarding its drug development pipeline.

Key Numbers

Key Players & Entities

FAQ

When did CalciMedica, Inc. file this 10-K?

CalciMedica, Inc. filed this Annual Report (10-K) with the SEC on March 28, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by CalciMedica, Inc. (CALC).

Where can I read the original 10-K filing from CalciMedica, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by CalciMedica, Inc..

What are the key takeaways from CalciMedica, Inc.'s 10-K?

CalciMedica, Inc. filed this 10-K on March 28, 2024. Key takeaways: CalciMedica, Inc. filed its 2023 Annual Report on Form 10-K on March 28, 2024.. The company was formerly known as Graybug Vision, Inc. and changed its name to CalciMedica, Inc. on March 22, 2023.. The filing covers the fiscal year ending December 31, 2023..

Is CalciMedica, Inc. a risky investment based on this filing?

Based on this 10-K, CalciMedica, Inc. presents a moderate-risk profile. The company's financial disclosures are limited in this excerpt, making it difficult to assess its overall financial health, profitability, or cash burn rate, which are critical for a clinical-stage biopharmaceutical company.

What should investors do after reading CalciMedica, Inc.'s 10-K?

Investors should review the full 10-K filing to understand CalciMedica's financial position, operational progress, and any forward-looking statements regarding its drug development pipeline. The overall sentiment from this filing is neutral.

How does CalciMedica, Inc. compare to its industry peers?

CalciMedica, Inc. operates within the pharmaceutical preparations sector, focusing on the development of novel therapeutics.

Are there regulatory concerns for CalciMedica, Inc.?

As a publicly traded company, CalciMedica is subject to the reporting requirements of the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.

Industry Context

CalciMedica, Inc. operates within the pharmaceutical preparations sector, focusing on the development of novel therapeutics.

Regulatory Implications

As a publicly traded company, CalciMedica is subject to the reporting requirements of the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934.

What Investors Should Do

  1. Review the full 10-K for detailed financial statements and management's discussion and analysis.
  2. Analyze the company's pipeline and clinical trial progress, if detailed in the report.
  3. Assess the impact of the name change and any related strategic shifts.

Key Dates

Year-Over-Year Comparison

This is the first 10-K filing for CalciMedica, Inc. under its current name, following a name change from Graybug Vision, Inc. in March 2023.

Filing Stats: 4,542 words · 18 min read · ~15 pages · Grade level 15.8 · Accepted 2024-03-28 16:19:15

Key Financial Figures

Filing Documents

Business

Business 2 Item 1A.

Risk Factors

Risk Factors 52 Item 1B. Unresolved Staff Comments 103 Item 1C. Cybersecurity 103 Item 2.

Properties

Properties 104 Item 3.

Legal Proceedings

Legal Proceedings 105 Item 4. Mine Safety Disclosures 105 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 106 Item 6. [Reserved ] 106 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 107 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 118 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 118 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 118 Item 9A.

Controls and Procedures

Controls and Procedures 118 Item 9B. Other Information 119 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 119 PART III Item 10. Directors, Executive Officers and Corporate Governance 120 Item 11.

Executive Compensation

Executive Compensation 120 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 120 Item 13. Certain Relationships and Related Transactions, and Director Independence 120 Item 14. Principal Accounting Fees and Services 120 PART IV Item 15. Exhibits, Financial Statement Schedules 121 Item 16. Form 10-K Summary 125 1

Bu siness

Item 1. Bu siness. Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates act upon calcium release-activated calcium (" CRAC ") channels, and would constitute a new class of drugs. We are a company focused on the discovery and development of CRAC channel inhibitors. Clinical and preclinical data have demonstrated that the inhibition of CRAC channels may have a therapeutic effect based on a dual mechanism involving both anti-inflammatory and tissue cell protective activities. Our work has shown compelling evidence of the involvement of CRAC channels in a broad spectrum of both acute critical illnesses and chronic diseases that have the common thread of inflammation or immunologic activity in their pathogenesis. We intend to leverage our CRAC channel inhibitor platform to develop therapeutics for indications where this dual mechanism of action has the potential for clinical benefit. Our lead product candidate is Auxora, a potent and selective intravenous (" IV ") formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. Multiple Phase 2 clinical trials with Auxora have been conducted: an open-label trial in acute pancreatitis (" AP "), an investigator led open label trial in asparaginase induced pancreatic toxicity (" AIPT ")(which we also refer to as " CRSPA ") in which the first cohort of patients has been completed, a placebo-controlled double-blind trial in severe COVID-19 pneumonia (which we also refer to as " CARDEA ") and an investigator led open-label trial in COVID-19 pneumonia patients with acute respiratory distress syndrome (" ARDS "). We observed in al

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing